Career records & work history
Medicine Doctors
Fei Zhang
Specialties:
Psychiatry
Fei Zhang, 37Millburn, NJ
Fei Zhang Phones & Addresses
Millburn, NJ
Chandler, AZ
Union, NJ
Tempe, AZ
Mentions for Fei Zhang
Fei Zhang resumes & CV records
Resumes
Fei Zhang
Fei M Zhang
Fei Zhang
Manager At Amgen
Position:
manager at amgen
Location:
United States
Industry:
Computer Hardware
Work:
amgen
manager
manager
Student At New York University - Leonard N. Stern School Of Business
Location:
Greater New York City Area
Industry:
Financial Services
Fei Zhang
Location:
United States
Buyer At Loreal
Location:
United States
Industry:
Cosmetics
Fei Zhang
Location:
United States
Publications & IP owners
Us Patents
Tartaric Acid Salts Of A Dipeptidyl Peptidase-Iv Inhibitor
US Patent:
2009012, May 14, 2009
Filed:
Mar 24, 2006
Appl. No.:
11/883907
Inventors:
Zhiguo J. Song - Edison NJ, US
Fei Zhang - Edison NJ, US
Rebecca Leigh Shultz - Maplewood NJ, US
Fei Zhang - Edison NJ, US
Rebecca Leigh Shultz - Maplewood NJ, US
International Classification:
A61K 31/551
C07D 223/10
C07D 223/10
US Classification:
514218, 540529
Abstract:
Tartaric acid salts of (3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl) butanoyl]hexahydro-3-(2,2,2-trifluoroethyl)-2H-1,4-diazepin-2-one are potent inhibitors of dipeptidyl peptidase-IV and are useful for the prevention and/or treatment of non-insulin dependent diabetes mellitus, also referred to as Type 2 diabetes. The invention also relates to crystalline anhydrate forms of the tartaric acid salts as well as a process for their preparation, pharmaceutical compositions containing these novel forms and methods of use for the treatment of Type 2 diabetes.
Rna-Nanostructured Double Robots And Methods Of Use Thereof
US Patent:
2022017, Jun 9, 2022
Filed:
Dec 16, 2021
Appl. No.:
17/553603
Inventors:
- Scottsdale AZ, US
Hao YAN - Chandler AZ, US
Xiaodong QI - Tempe AZ, US
Fei ZHANG - Chandler AZ, US
Hao YAN - Chandler AZ, US
Xiaodong QI - Tempe AZ, US
Fei ZHANG - Chandler AZ, US
International Classification:
C12N 15/117
A61K 39/00
A61K 39/00
Abstract:
Described herein are immuno-stimulatory RNA nanostructures (which comprises a single-stranded RNA (ssRNA) molecule, wherein the ssRNA molecule forms at least one paranemic cohesion crossover), as well as compositions and methods of use thereof.
Rna Nanostructures And Methods Of Making And Using Rna Nanostructures
US Patent:
2021024, Aug 12, 2021
Filed:
Aug 30, 2018
Appl. No.:
16/642792
Inventors:
- Scottsdale AZ, US
Yung CHANG - Tempe AZ, US
Xiaowei LIU - Tempe AZ, US
Fei ZHANG - Chandler AZ, US
Xiaodong QI - Tempe AZ, US
Yung CHANG - Tempe AZ, US
Xiaowei LIU - Tempe AZ, US
Fei ZHANG - Chandler AZ, US
Xiaodong QI - Tempe AZ, US
International Classification:
C12N 15/117
Abstract:
Certain embodiments provide RNA nanostructure (e.g., comprising one single-stranded RNA (ssRNA) molecule, wherein the RNA nanostructure comprises at least one paranemic cohesion crossover), as well as compositions and methods of use thereof. In certain embodiments, such RNA nanostructures are immuno-modulatory (e.g., immuno-stimulatory).
Rna-Nanostructured Double Robots And Methods Of Use Thereof
US Patent:
2020038, Dec 10, 2020
Filed:
Jan 10, 2019
Appl. No.:
16/954458
Inventors:
- Skysong - Suite 200 AZ, US
Hao YAN - Chandler AZ, US
Xiaodong QI - Tempe AZ, US
Fei ZHANG - Chandler AZ, US
Hao YAN - Chandler AZ, US
Xiaodong QI - Tempe AZ, US
Fei ZHANG - Chandler AZ, US
International Classification:
C12N 15/117
A61K 39/00
A61K 39/00
Abstract:
Described herein are immuno-stimulatory RNA nanostructures (which comprises a single-stranded RNA (ssRNA) molecule, wherein the ssRNA molecule forms at least one paranemic cohesion crossover), as well as compositions and methods of use thereof.
Possible Relatives
NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.